Please assess the completion status of the following clinical trial:

Trial Title: 12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Patients \>=18 years with type 2 diabetes~2. HbA1c of \>= 7.0% (53 mmol/mol) and =\< 10% (86 mmol/mol)~3. Mean seated systolic blood pressure 130-159 mmHg and diastolic blood pressure 80-99 mmHg~Exclusion criteria:~1. Uncontrolled hyperglycaemia with a glucose level \>240 mg/dl (\>13.3 mmol/L) after an overnight fast before randomization~2. Known or suspected secondary hypertension~3. Acute coronary syndrome (non-STEMI, STEMI and unstable angina pectoris), stroke or transient ischemic attack within 3 months prior to informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BI 10773 low dose (Type: EXPERIMENTAL): BI 10773 low dose once daily
- BI 10773 high dose (Type: EXPERIMENTAL): BI 10773 high dose once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets matching BI 10773

Based on this trial design, predict the completion outcome and termination type (if applicable).